---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-031366"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2023-07-03T23:59:59+00:00"
generated_at: "2026-06-13T13:22:13.230865+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Renalytix appoints Catherine Coste to Board of Directors as Audit Chair

## Summary
- Catherine Coste, former Deloitte senior partner, appointed to board effective June 30, 2023.
- She will serve as Non-Executive Chair of Audit Committee and member of Remuneration Committee.
- Compensation: $40k/year director fee, plus $20k for Audit Chair, $7k for Remuneration Committee.
- Coste has 32 years finance experience, CPA, and serves on two other public company boards.

## SEC filing metadata
- accession: 0000950170-23-031366
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2023-07-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017023031366/0000950170-23-031366-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017023031366/rnlx-20230701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-031366
- JSON: https://secwatch.observer/filing/0000950170-23-031366.json
- Plain text: https://secwatch.observer/filing/0000950170-23-031366.txt

## Key facts
- Executive change
  Catherine Coste was appointed as Director at Renalytix plc.
  - Action: appointed
  - Role: Director
  source text: On June 30, 2023, Catherine Coste was appointed to the Board of Directors (the “Board”) of Renalytix plc (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023031366/0000950170-23-031366-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.